CORE--IMAGING

核心--成像

• 批准号: 8013844
• 负责人: DAVID A. BLUEMKE
• 金额: $ 28.72万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8013844
• 关键词: Biological Markers; Blood Vessels; Cardiac; Cardiovascular Physiology; Cardiovascular system; Data; Deterioration; Disease; Disease Marker; Echocardiography; Evaluation; Failure; Fibrosis; Goals; Human Resources; Image; Imaging Techniques; Inflammation; Lung; Lung diseases; Magnetic Resonance Imaging; Measurement; Measures; Molecular; Myocardial; Myocardial dysfunction; Patients; Phenotype; Proteomics; Pulmonary artery structure; Research Infrastructure; Resources; Right Ventricular Dysfunction; Right Ventricular Function; Right ventricular structure; Scleroderma; Serological; Services; Structure; Testing; Validation; Ventricular; base; design; detector; experience; imaging modality; mortality; novel; pressure; pulmonary arterial hypertension; pulmonary function

Right ventricular failure is the most important predictor of mortality for patients with severe pulmonary arterial hypertension (PAH). Based on the preliminary data of Projects 1, 2, and 3, patients with scleroderma-associated PAH-(SSc) have a significantly higher rate of right ventricular failure for the same levels of pulmonary artery pressures as patients with IPAH. Since the overall goal of our SCCOR is to understand the molecular mechanisms of right ventricular failure, increase the accuracy of phenotyping of patients, with severe PAH and to test novel therapies, an imaging core is central for several of the goals of this proposal. The primary functions of the Imaging Core are to provide comprehensive analysis and interpretation of multiple imaging biomarkers, and to develop and test novel imaging biomarkers. These imaging parameters will serve to (a) characterize extent and progression of right ventricular disease associated with PAH (with Projects 1,2, 3); (b) phenotype cardiovascular function to facilitate interpretation of serologic and proteomic markers in PAH (with Cores C, D and F and Projects 1, 2 and 3), and (c) develop/ test/ evaluate novel imaging biomarkers in terms of their sensitivity and their predictive potential for disease characterization (with Projects 1,2 and 3). Therefore, the Imaging Core will be involved actively in phenotype characterization, and biomarker discovery and validation. The right ventricle is negatively impacted by pulmonary disease, and deterioration in global RV structure and function have been measured previously using echocardiography, magnetic resonance imaging (MRI) and multi-detector CT (MDCT). The overall strategy of the imaging core will be to (1) provide reliable measurements of echocardiographic derived cardiac function, (2) provide reliable measurements of MRI and MDCT derived cardiac and pulmonary vascular function, and (3) implement novel imaging methods designed to measure regional myocardial dysfunction and myocardial fibrosis/ inflammation. Overall, we aim to comprehensively characterize RV status by assessing RV global function, RV regional function, pulmonary distensibility and RV fibrosis using noninvasive imaging methods.

右心室衰竭是严重肺动脉高压患者死亡率的最重要预测因素。 动脉高血压（PAH）。根据项目1、2和3的初步数据， 硬皮病相关PAH-（SSc）的右心室衰竭发生率显著更高， IPAH患者的肺动脉压水平。由于我们SCCOR的总体目标是 了解右心室衰竭的分子机制，提高表型的准确性， 对于重度PAH患者和测试新疗法，成像核心对于以下几个目标至关重要： 这个提议。成像核心的主要功能是提供全面的分析和 解释多种成像生物标志物，并开发和测试新的成像生物标志物。这些 成像参数将用于（a）表征右心室疾病的程度和进展 与PAH相关（项目1、2、3）;（B）表型心血管功能，以便于解释 PAH的血清学和蛋白质组学标志物（核心C、D和F以及项目1、2和3），以及（c） 开发/测试/评估新的成像生物标志物的灵敏度和预测潜力 疾病特征描述（项目1、2和3）。因此，成像核心将积极参与 在表型表征和生物标志物发现和验证方面。 右心室受到肺部疾病和整体RV结构恶化的负面影响 和功能以前已经使用超声心动图，磁共振成像（MRI） 和多探测器CT（MDCT）。成像核心的总体战略将是（1）提供可靠的 超声心动图衍生的心脏功能测量，（2）提供MRI的可靠测量 和MDCT导出的心脏和肺血管功能，以及（3）实现新的成像方法 旨在测量局部心肌功能障碍和心肌纤维化/炎症。总的来说，我们 旨在通过评估RV整体功能、RV局部功能 肺膨胀性和RV纤维化。